Depression Drugs Market: IntroductionAccording to the report, the global depression drugs market was valued at US$ 18.9 Bn in 2019 and is projected to expand at a CAGR of ~2% from 2020 to 2030.
Major depressive disorder (MDD), schizophrenia and bipolar I disorder, Obsessive-Compulsive Disorders (OCD), and anxiety disorder are some of the different types of depression.
These include Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), atypical antidepressants, and tricyclic antidepressants.
Rise in prevalence of depression and increase in incidence of depression among the geriatric population is boosting the global depression drugs.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1151 North America dominated the global depression drugs market in 2019.
Depression is the leading cause of disability among people aged between 15 and 44 in the U.S. More than 41,000 suicides are committed every year in the U.S. Depression is one of the most common illnesses among the elderly population.
Increase in number of depression drugs being dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries make these a major channel of distribution.North America to Lead Global MarketThe global depression drugs market has been split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.